Literature DB >> 9736536

Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.

J Turner1, Y Cho, N N Dinh, A J Waring, R I Lehrer.   

Abstract

Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736536      PMCID: PMC105778          DOI: 10.1128/AAC.42.9.2206

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  The solution structure of the active domain of CAP18--a lipopolysaccharide binding protein from rabbit leukocytes.

Authors:  C Chen; R Brock; F Luh; P J Chou; J W Larrick; R F Huang; T H Huang
Journal:  FEBS Lett       Date:  1995-08-14       Impact factor: 4.124

Review 2.  Antibiotic proteins of polymorphonuclear leukocytes.

Authors:  O Levy
Journal:  Eur J Haematol       Date:  1996-05       Impact factor: 2.997

Review 3.  Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain.

Authors:  M Zanetti; R Gennaro; D Romeo
Journal:  FEBS Lett       Date:  1995-10-23       Impact factor: 4.124

4.  The structure of porcine protegrin genes.

Authors:  C Zhao; T Ganz; R I Lehrer
Journal:  FEBS Lett       Date:  1995-07-17       Impact factor: 4.124

Review 5.  Structure, function, and membrane integration of defensins.

Authors:  S H White; W C Wimley; M E Selsted
Journal:  Curr Opin Struct Biol       Date:  1995-08       Impact factor: 6.809

6.  Neutrophil defensins: purification, characterization, and antimicrobial testing.

Authors:  S S Harwig; T Ganz; R I Lehrer
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

7.  Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein.

Authors:  J W Larrick; M Hirata; R F Balint; J Lee; J Zhong; S C Wright
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

8.  Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins.

Authors:  O Levy; C E Ooi; P Elsbach; M E Doerfler; R I Lehrer; J Weiss
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

9.  Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs.

Authors:  T J VanderMeer; M J Menconi; J Zhuang; H Wang; R Murtaugh; C Bouza; P Stevens; M P Fink
Journal:  Surgery       Date:  1995-06       Impact factor: 3.982

10.  Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense.

Authors:  D P Speert; M Bond; R C Woodman; J T Curnutte
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

View more
  241 in total

1.  The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa.

Authors:  J Malm; O Sørensen; T Persson; M Frohm-Nilsson; B Johansson; A Bjartell; H Lilja; M Ståhle-Bäckdahl; N Borregaard; A Egesten
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 2.  Antimicrobial polypeptides in host defense of the respiratory tract.

Authors:  Tomas Ganz
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Congeners of SMAP29 kill ovine pathogens and induce ultrastructural damage in bacterial cells.

Authors:  V C Kalfa; H P Jia; R A Kunkle; P B McCray; B F Tack; K A Brogden
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 4.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects.

Authors:  Amy A Baxter; Fung T Lay; Ivan K H Poon; Marc Kvansakul; Mark D Hulett
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

5.  The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6.

Authors:  M Frohm Nilsson; B Sandstedt; O Sørensen; G Weber; N Borregaard; M Ståhle-Bäckdahl
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 6.  Epithelial cells and innate antifungal defense.

Authors:  G Weindl; J Wagener; M Schaller
Journal:  J Dent Res       Date:  2010-04-15       Impact factor: 6.116

7.  Peptide antibiotic sensing and detoxification modules of Bacillus subtilis.

Authors:  Anna Staroń; Dora Elisabeth Finkeisen; Thorsten Mascher
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 8.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

Review 9.  Recent advances in nanomedicine for sepsis treatment.

Authors:  Simseok A Yuk; Diego A Sanchez-Rodriguez; Michael D Tsifansky; Yoon Yeo
Journal:  Ther Deliv       Date:  2018-05-01

10.  Susceptibilities of oral bacteria and yeast to mammalian cathelicidins.

Authors:  J M Guthmiller; K G Vargas; R Srikantha; L L Schomberg; P L Weistroffer; P B McCray; B F Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.